Abstract: The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. Preferably said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.
Type:
Grant
Filed:
September 9, 2000
Date of Patent:
July 1, 2003
Assignee:
Akzo Nobel
Inventors:
Ronald Montelaro, Bridget Puffer, Feng Li, Charles Issel, Kristina J. Hennessy, Karen K. Brown
Abstract: A live attenuated Venezuelan equine encephalitis virus (VEE) is described which comprises a viral gene rearrangement. This rearranged attenuated virus is useful as vaccine for protection against infection with VEE. Methods of preparing the virus and methods of using the virus are described.
Type:
Grant
Filed:
December 7, 1999
Date of Patent:
October 2, 2001
Assignee:
The United States of America as represented by the Secretary
of the Army
Inventors:
Peter Pushko, Michael D. Parker, Jonathan F. Smith, Bruce J. Crise
Abstract: An Equine herpesvirus-4 (EHV-4) mutant which does not produce a functional thymidine kinase due to a deletion and/or insertion in the gene encoding thymidine kinase, the deletion and/or insertion made at a position within the thymidine kinase gene such as to not substantially alter expression of the UL24 gene. Recombinant DNA comprising DNA of the EHV-4 mutant, host cells containing the recombinant DNA, and a process for the preparation of the EHV-4 mutant.
Type:
Grant
Filed:
November 7, 1997
Date of Patent:
February 15, 2000
Assignees:
University Court of the University of Glasgow, Equine Virology Research Foundation